Cholesterol is an important part of your body’s health, but too much of the wrong kind can lead to serious problems like ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe ... spark renewed debate about fairness and the cost of new drugs, although it should be noted that the price of both ...

Evolucumab (Repatha) and alirocumab (Praluent) are injectable monoclonal antibodies. They have been joined by inclisiran ...

Q. Allergan ran a long-term study on silicone breast implants in 2009. I always wanted a more feminine body like the girls in the magazines, so I joined and got implants. They never followed up with ...

Repatha, which treats cholesterol and heart disease, and EVENITY, which targets osteoporosis in postmenopausal women, are drugs that are continually delivering strong growth for the company.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Wall Street drifted higher as gains for most stocks outweighed drops for Alphabet and some other big-name companies following their latest earnings reports ...

Amgen’s biggest growth drivers in the quarter were asthma drug Tezpire, osteoporosis drugs Evenity and Prolia, and cholesterol-lowering drug Repatha. These drugs were able to counter relatively ...

It reported stronger profit for the latest quarter than expected, thanks in part to growth for its Repatha medicine, which can lower bad cholesterol and reduce the risk of heart attack.

general medicine outperformed, with Repatha and Evenity delivering the strongest growth. The former drug represents a new approach to cardiovascular health (lowering LDL cholesterol), while the ...